Savient Pharma - 500 Beiträge pro Seite

[blb]

Hat jemand von euch Infos zu Savient (SVNT)? Die Fundamentals sehen auf den ersten Blick gut aus, mir gefällt v.a. die niedrige Bewertung.



Grüße
blb

[blb]

- Savient Pharma [SVNT]
- Aktueller Börsenwert um die 270 Millionen $
- Puricase mit erfolgreicher Phase II vor Eintritt in Phase III
- 1. Quartal Umsatz: 22 Millionen $
- Verlust 3,8 Millionen $, 6 Cent per Aktie
- Cash zwar nur 27 Millionen $, Assets aber rund 120 Millionen $
- Mehrer Produkte bereits auf dem Markt

[blb]

Zahlen:

Savient Pharmaceuticals Reports Unaudited Results for First Quarter 2005; Management Advances Company`s Strategy
TUESDAY, MAY 10, 2005 6:50 AM
- BusinessWire

EAST BRUNSWICK, N.J., May 10, 2005 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc., (SVNT) an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, announced today unaudited results for the first quarter 2005.

For the first quarter of 2005, total revenues were $23.0 million, down from $33.4 million a year ago. The net loss for the first quarter was $3.9 million, or 6 cents per share, compared to net income of $1.2 million, or 2 cents per share, a year ago.

Christopher Clement, President and Chief Executive Officer of Savient, said, "Rosemont Pharmaceuticals, our U.K.-based oral liquids pharmaceutical business, reported another excellent quarter with sales up 26%. These gains were offset, however, by a decline in U.S. sales of Oxandrin(R) due primarily to customer inventory reductions, additional credits and reserves for outdated product, rebates and wholesaler distribution fees, coupled with reduced prescription demand for the overall involuntary weight loss market, including Oxandrin.

"The first quarter results reflect, in part, the execution of our strategy shared with you last July. At that time, we announced our intentions to explore the sale of our global biologics manufacturing business and direct the proceeds to increasing the geographic reach of Rosemont and advancing our drug development pipeline. We remain committed to executing our strategy and remain confident in our abilities to effectively change the direction of Savient."

Clement highlighted the major accomplishments of the first quarter of 2005 to advance the Company`s strategy, including:

-- The successful completion of the Phase 2 clinical trial for Puricase(R), a rheumatology-directed drug candidate for the treatment of severe, refractory gout, with data being released in the next two weeks;

-- The receipt of $3 million in an initial settlement of damages and attorney fees claims related to human growth hormone intellectual property disputes with Novo Nordisk SA;

-- The payment of $2.25 million in settlement of a lawsuit in Israel with Genentech regarding hGH patent disputes, the last outstanding such litigation;

-- The announced agreement to sell the global biologics manufacturing business to Ferring for $80 million cash;

-- The announced agreement with Ferring to co-promote Nuflexxa(TM) for the treatment of pain in osteoarthritis of the knee in the United States, thereby providing the potential for near-term revenue in support of a rheumatologist-focused sales force;

-- Early termination of the Prosaptide(TM) Phase 2 trial at a scheduled interim analysis for lack of analgesic efficacy. This interim analysis enabled the Company to manage the trial efficiently and make crucial decisions as early as possible, thereby conserving critical funding resources;

-- The further strengthening of the Company`s management team with the addition of a Senior Vice President of Commercial Operations and a Vice President of Business Development; and

-- The continued improvement of our balance sheet with increased cash and decreased debt.

Quarter Ended March 31, 2005

Revenues

-- Total revenues for the three months ended March 31, 2005 were $23.0 million compared to $33.4 million a year ago.

-- Net product sales were $22.6 million compared to $32.2 million a year ago.

-- Net product sales of Rosemont`s oral liquid pharmaceuticals increased 26% to $9.1 million or 22%, excluding the effects of a stronger British pound.

-- Net sales of Oxandrin in the first quarter were $8.3 million compared to $18.4 million last year, reflecting a $4.2 million reduction in a drug wholesaler`s inventory levels, additional credits and reserves of $4.8 million for outdated product (driven by wholesalers` increasing to 12-month terms from 7 months the remaining minimum dating on product shipped to retail pharmacies), higher rebates and newly instituted wholesaler distribution fees, coupled with reduced prescription demand for the overall involuntary weight loss market, including Oxandrin. The market declined 1% for the year and declined 3% for the most recent quarter, measured in terms of total prescriptions. Total prescriptions for Oxandrin declined 7% versus a year ago and 6% versus the immediately preceding quarter. Most recently, total prescriptions increased 8% in March, ending six-months of a declining trend.

-- Net sales of Delatestryl(R) were $1.1 million down from $2.7 million a year earlier as generics captured 47% of market unit volume.

-- Total revenues for the global biologics manufacturing business were $4.1 million, approximately the same as revenues of a year ago.

Expenses

-- Total expenses for the first quarter were $28.6 million, down 10% from a year ago, reflecting lower marketing expense and research and development costs offset by higher general and administrative expenses for the wrap up of the Company`s Sarbanes-Oxley 2004 audit and compliance initiatives.

-- Cost of sales as a percentage of net product sales increased to 39% in the first quarter from 27% a year ago, reflecting a change in product mix and an increases in returned goods and inventory reserves.

Other Income

-- Other income of $2.1 million compared favorably to $0.1 million last year primarily as a result of the successful settlement of intellectual property litigation with Novo Nordisk SA.

Balance Sheet

-- Savient had cash, cash equivalents and short-term investments of $26.7 million at March 31, 2005 up from $25.3 million at year end, with a further reduction in long-term debt to $4.1 million.

Summary

Clement stated, "Oxandrin was a clear disappointment for the quarter. Our new commercial leadership and ongoing evaluation of the effectiveness of our related sales and marketing support should benefit the brand`s future performance in advance of a potential generic competitor.

"On the positive front, we are very pleased with our progress this quarter toward the evolution of our new strategic focus. The announced divestiture of our global biologics manufacturing business was a critical first step, and we remain confident this transaction will close before the end of the first half of the year. The continued expansion and growth of Rosemont, our oral liquids business, was another important step as we await the approval of our first product, Soltamox(R), in the United States later this year following the FDA`s completion of its inspection of our manufacturing facility yesterday. We continue to be encouraged by our steady progress in the development of our lead drug candidate, Puricase, and look forward to an end-of-Phase 2 meeting with the FDA in July to define the critical components of the Phase 3 program. And lastly, we look ahead to building a new commercial infrastructure here in the U.S. with our rheumatology-focused sales and marketing team who will initially focus on the co-promotion of Nuflexxa with Ferring.

"The milestones achieved this quarter signify our commitment to transforming Savient into a specialty pharmaceutical company by advancing our proprietary development projects. I look forward to the remainder of 2005 being a year of continued transformation and delivering results for the many valued shareholders of Savient."

Savient will host a conference call/live webcast today to review first quarter 2005 results today, May 10, 2005, at 11:00 a.m. EDT.

The live webcast can be accessed under the webcast page under the News section of Savient`s website at www.savientpharma.com and will be archived through June 7, 2005.

In addition, an audio replay will be available until May 24, 2005. The replay numbers are [phone] for domestic callers and [phone] for international callers. The replay access code is 9746867.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc., an emerging specialty pharmaceuticals company, is engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs in both niche and wider markets. Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company`s subsidiary, Rosemont Pharmaceuticals Limited, develops, manufactures, and markets through its own sales force oral liquid formulations of prescription products for the UK pharmaceutical market. Savient`s product Mircette(R), an oral contraceptive, is marketed by its licensee, Organon, Inc. Savient`s news releases and other information are available on the Company`s website at www.savientpharma.com. Mircette is a registered trademark of Organon, Inc. and Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding the Company`s strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, the statements regarding the divestiture of the Company`s global biologics manufacturing business and the potential for commercializing the Company`s Puricase drug product candidate are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company`s business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the possibility that the divestiture of our global biologics manufacturing business will fail to close, due to failure to achieve regulatory approval or otherwise; delay or failure in developing Prosaptide, Puricase and other product candidates; difficulties of expanding the Company`s product portfolio through in-licensing; disruption of management and costs associated with the divestiture of the Company`s operations in Israel; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company`s products; economic, political and other risks associated with foreign operations; risks of maintaining protection for the Company`s intellectual property; risks of an adverse determination in on-going or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company`s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company`s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not assume any obligation to update any forward-looking statements.

SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands except per share data)

Three Months Ended
March 31,

2005 2004
------------ -----------
Revenues:
Product sales, net 22,615 32,201
Contract fees 291 230
Royalties - 932
Other 75 40
------------ -----------
Total revenues 22,981 33,403
------------ -----------

Expenses:
Cost of sales 8,721 8,651
Research and development 6,282 8,664
Marketing and sales 5,154 6,666
General and administrative 6,177 5,372
Commissions and royalties 1,224 1,403
Amortization of intangibles and negative
goodwill associated with acquisitions 1,013 1,013
------------ -----------
Total expenses 28,571 31,769
------------ -----------

Operating (loss) income (5,590) 1,634
Other income (expense) - net 2,057 73
------------ -----------
(Loss) income before income taxes (3,533) 1,707
Income tax expense 332 529
------------ -----------
Net (Loss) Income (3,865) 1,178
============ ===========

(Loss) earnings per common share:
Basic:
Net (loss) income (0.06) 0.02
============ ===========
Diluted:
Net (loss) income (0.06) 0.02
============ ===========

Weighted average number of common
and common equivalent shares:
Basic 60,545 59,734
============ ===========
Diluted 60,545 60,331
============ ===========



SAVIENT PHARMACEUTICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)


March 31, December
2005 31, 2004
(unaudited)
----------- ---------
Assets:
Cash, cash equivalents and short-term
investments 26,668 25,282
Accounts receivable, net 1,185 6,118
Inventories, net 12,870 15,456
Other current assets 2,492 1,677
Assets available for sale 75,616 80,851
----------- ---------
Total current assets 118,831 129,384

Property and equipment, net 6,851 6,985
Intangible assets, net 70,675 71,688
Goodwill 40,121 40,121
Other long term-assets 1,365 2,991
----------- ---------
Total assets 237,843 251,169
=========== =========

Liabilities and stockholders` equity:
Current portion of long-term debt 4,144 5,903
Liabilities available for sale 11,954 12,743
Other current liabilities 23,549 29,998
Long-term debt 0 0
Other long-term liabilities and deferred items 47,313 47,857
Stockholders` equity 150,883 154,668
----------- ---------
Total liabilities and stockholders` equity 237,843 251,169
=========== =========


SOURCE: Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc.
Investor Relations
Jenene Thomas, 732-565-4716
[e-mail]
or
The Ruth Group
Investors/Media:
Stephanie Carrington / Janine McCargo
646-536-7017/7033
[e-mail]
[e-mail]


Copyright Business Wire 2005

[blb]

Puricase:

Savient Pharmaceuticals Reports Positive Top-Line Results for Puricase Phase 2 Trial
THURSDAY, MAY 12, 2005 2:08 PM
- BusinessWire

EAST BRUNSWICK, N.J., May 12, 2005 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (SVNT) , an emerging specialty pharmaceuticals company focused on addressing the unmet medical needs in both niche and broader markets, announced today the positive top-line results of its completed Phase 2 trial for its lead drug candidate, Puricase(R). This trial was designed to test the safety and efficacy of Puricase in patients with symptomatic gout who are intolerant of or unresponsive to conventional therapy. The Company estimates approximately 35,000 to 50,000 patients in the United States. The U.S. Food and Drug Administration (FDA) granted the Company an Orphan designation to study Puricase in this patient population.

Puricase is a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase) which was studied in a recently completed Phase 2 trial initiated in early 2004. The primary objective of the study was to determine the most appropriate dosing for a pivotal Phase 3 clinical trial, upon which the registration will be based. The Company believes that this objective has been achieved.

The Phase 2 study was a randomized, open label, parallel design trial. Forty-one patients were randomized to receive Puricase as an intravenous infusion administered once every two weeks (4 mg or 8 mg), or once every four weeks (8 mg or 12 mg), for a three-month treatment period. At entry, the mean age of the patients was 58.1 years. Eighty-five percent of the patients were male and 83% were Caucasian. The mean duration of the disease history was 14 years and one or more gout tophi were present in 70% of the patients.

The following data are reported as within group comparisons to baseline, group means, in the "intent-to-treat" population shown by dosing group.

The maximum percent decrease in plasma uric acid from baseline
within the first 24 hours of Puricase dosing:

-- 4 mg / 2 weeks - 72% (p equals .0002)
-- 8 mg / 2 weeks - 94% (p less than .0001)
-- 8 mg / 4 weeks - 87% (p less than .0001)
-- 12 mg / 4 weeks - 93% (p less than .0001)

The percent decrease in plasma uric acid from baseline over the
12-week treatment period:

-- 4 mg / 2 weeks - 38% (p equals .0002)
-- 8 mg / 2 weeks - 86% (p less than .0001)
-- 8 mg / 4 weeks - 58% (p equals .0003)
-- 12 mg / 4 weeks - 67% (p less than .0001)


All dose groups maintained for the twelve-week treatment period the mean plasma uric acid levels below the prospectively planned success criterion of 6mg/dL. The 4 mg dose showed the least decrease in uric acid, and 12 mg was not meaningfully better than 8 mg. A dose of 8 mg every two weeks and every four weeks will be recommended for Phase 3.

Dr. Zeb Horowitz, Chief Medical Officer, Savient Pharmaceuticals said, "The efficacy of Puricase in reducing uric acid is in line with our expectations. Interestingly, anecdotal reports by study patients of clinical outcomes such as eradication of gout tophi, improvements in joint functioning and general improvements in the sense of well being were unexpected and remarkable. These potentially important and novel benefits of Puricase treatment will be studied formally in Phase 3. If confirmed in a Phase 3 trial, we believe Puricase could evolve into the first disease-modifying treatment for severe, refractory gout."

During the trial, patients in all dose groups exhibited adverse events typically associated with severe gout, e.g., gout flares, breakdown of gout tophi, or symptoms of gouty arthritis. This finding is not surprising considering that eligibility for the trial required a medical history of symptomatic gout. Additionally, adverse events associated with the intravenous infusion of Puricase occurred, which is not unusual for biological agents. For most of the study, Puricase had been administered as a 30-minute infusion. The duration of the infusion was later extended to 60 minutes. Thereafter, patients experienced fewer infusion reactions. Although manifestations of reactive antibody generation were not observed in Phase 2, the potential for development of anti-Puricase antibodies will be studied in Phase 3 as part of a comprehensive assessment of safety and efficacy.

Horowitz stated, "These results lead us to believe that Puricase may become the first effective therapy for this population of previously untreatable patients. We believe the rapid, dramatic, and sustained reduction in uric acid we have seen in this trial and in our Phase 1 program, together with the emerging safety profile, provides a solid foundation for moving into Phase 3."

Abstracts detailing the safety and efficacy data from this trial have been submitted for consideration for presentation at the November 2005 Annual Meeting of the American College of Rheumatology. In addition, the FDA has granted a late July 2005 date for an end-of-Phase 2 meeting to define the critical components of the Phase 3 program and data requirements for drug registration. The Company plans to initiate a Phase 3 clinical program by November 2005, contingent upon the outcome of the meeting with the FDA.

Savient licensed worldwide rights to the technologies related to Puricase from Duke University ("Duke") of North Carolina and Mountain View Pharmaceuticals, Inc. ("MVP"), a California corporation. Duke developed the recombinant porcine uricase enzyme and MVP developed the PEGylation technology to prolong its duration of action and enhance its safety by reducing the potential for immune responses. MVP and Duke were granted U.S. and foreign patents covering the licensed technology.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc., an emerging specialty pharmaceuticals company, is engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs in both niche and wider markets. Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company`s subsidiary, Rosemont Pharmaceuticals Limited, develops, manufactures, and markets through its own sales force oral liquid formulations of prescription products for the UK pharmaceutical market. Savient`s product Mircette(R), an oral contraceptive, is marketed by its licensee, Organon, Inc. Savient`s news releases and other information are available on the Company`s website at www.savientpharma.com. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding the Company`s strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, the statements regarding the divestiture of the Company`s global biologics manufacturing business and the potential for commercializing the Company`s Puricase drug product candidate are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company`s business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the possibility that the divestiture of our global biologics manufacturing business will fail to close, due to failure to achieve regulatory approval or otherwise; delay or failure in developing Prosaptide, Puricase and other product candidates; difficulties of expanding the Company`s product portfolio through in-licensing; disruption of management and costs associated with the divestiture of the Company`s operations in Israel; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company`s products; economic, political and other risks associated with foreign operations; risks of maintaining protection for the Company`s intellectual property; risks of an adverse determination in on-going or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company`s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company`s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not assume any obligation to update any forward-looking statements.

SOURCE: Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc.
Jenene Thomas, 732-565-4716
[e-mail]
or
The Ruth Group
Investors/Media:
Stephanie Carrington/Gregory Tiberend
646-536-7017/7005
[e-mail]
[e-mail]


Copyright Business Wire 2005

[blb]

Ende des Monats soll die Transaktion abgeschlossen sein, das spült dann sofort 55 Millionen $ in die Kasse!

Savient Pharmaceuticals to Sell Global Biologics Manufacturing Business for $80 Million; Major Milestone Achieved in Savient`s New Strategic Direction
WEDNESDAY, MARCH 23, 2005 7:31 AM
- BusinessWire

EAST BRUNSWICK, N.J., Mar 23, 2005 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (SVNT) , today announced that it has signed a definitive agreement to sell its global biologics manufacturing business for $80 million cash to Ferring B.V. and Ferring International Centre SA, subsidiaries of Ferring Holding SA, a privately owned specialty biopharmaceutical company headquartered in Lausanne, Switzerland. Savient will receive the $80 million in three installments: $55 million at closing, $15 million at the first anniversary of closing and $10 million at the second anniversary of closing. Savient estimates the proceeds from this transaction over the next two years to be approximately $70 million after transaction-related expenses, taxes and the extinguishment of bank debt, assuming the transaction closes in the next six months. The closing of the transaction, which has been approved by the boards of directors of both companies, is subject to a number of conditions, including certain governmental and regulatory approvals. Savient expects that the transaction will close by the end of the first half of 2005.

The sale is part of Savient`s new strategic direction announced in July 2004 to reposition Savient to focus on the full development of its pipeline products. As part of this new strategic direction, Savient announced its intention to explore the sale of its global biologics manufacturing business and to use the proceeds from the divestiture to fund the advancement of its lead drug candidate Puricase for the treatment of severe, refractory gout which is nearing completion of Phase 2 clinical trials in the United States, and pursue business development opportunities to in-license novel compounds in clinical stage development as well as marketed products complimentary to this strategy.

Christopher Clement, Chief Executive Officer and President, stated, "The signing of this agreement represents a major milestone for Savient and aligns well with our new strategic focus as an emerging specialty pharmaceutical company. Most importantly, the transaction provides us with the capital to drive the advancement of Puricase into Phase 3 clinical trials and to pursue licensing or acquisition opportunities of novel compounds in clinical development as well as marketed products that satisfy the unmet medical needs of the rheumatology specialist, our therapeutic area of initial focus."

Savient`s global biologics manufacturing business features a diverse portfolio of seven products that include Bio-Tropin(TM) human growth hormone (marketed as TevTropin(TM) in the United States), Nuflexxa(R) hyaluronic acid for amelioration of knee pain due to osteoarthritis (to be marketed outside the United States under the tradename Euflexxa(TM)), BioLon(R) hyaluronic acid for use in surgery, Bio-Hep-B(TM) recombinant hepatitis B vaccine, insulin, Fibrimage(R) radiopharmaceutical product for diagnosis of deep vein thrombosis and pulmonary embolism, and a development stage generic biologic product.

Savient and Ferring have also agreed to enter a co-promotion agreement for Nuflexxa in the United States, contingent upon the completion of the sale of the global biologics manufacturing business.

Christopher Clement, President and Chief Executive Officer, will host a conference call/live webcast to review this transaction in detail today, March 23, 2005 at 11:00 a.m. EST.

The live webcast can be accessed from the investor relations page of Savient`s website at www.savientpharma.com and will be archived through April 23, 2005.

In addition, an audio replay will be available until April 6, 2005. The replay numbers are [phone] for domestic callers and [phone] for international callers. The replay Conference ID Number is 144917.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc., an emerging specialty pharmaceuticals company, is engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs in both niche and wider markets. Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company`s subsidiary, Rosemont Pharmaceuticals Limited, develops, manufactures, and markets through its own sales force oral liquid formulations of prescription products for the UK pharmaceutical market. Savient`s product Mircette(R), an oral contraceptive, is marketed by its licensee, Organon, Inc. Savient`s news releases and other information are available on the Company`s website at www.savientpharma.com. Mircette is a registered trademark of Organon, Inc. and Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding the Company`s strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, the statements regarding the divestiture of the Company`s global biologics manufacturing business and the potential for commercializing the Company`s Puricase drug product candidate are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company`s business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the possibility that the divestiture of our global biologics manufacturing business will fail to close, due to failure to achieve regulatory approval or otherwise; our ability to complete the audit of our financial statements for the year ended December 31, 2004; delay or failure in developing Prosaptide, Puricase and other product candidates; difficulties of expanding the Company`s product portfolio through in-licensing; disruption of management and costs associated with the divestiture of the Company`s operations in Israel; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company`s products; economic, political and other risks associated with foreign operations; risks of maintaining protection for the Company`s intellectual property; risks of an adverse determination in on-going or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company`s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company`s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not assume any obligation to update any forward-looking statements.

SOURCE: Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc.
Jenene Thomas, 732-565-4716
[e-mail]
or
The Ruth Group
Investors/Media:
Stephanie Carrington/Gregory Tiberend
646-536-7017/7005
[e-mail]
[e-mail]


Copyright Business Wire 2005

[blb]

Die 55 Millionen $ sind auf dem Konto!

Savient Pharmaceuticals Closes Sale of Global Biologics Manufacturing Business; Major Milestone Achieved
MONDAY, JULY 18, 2005 11:34 AM
- BusinessWire

EAST BRUNSWICK, N.J., Jul 18, 2005 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (SVNT) an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, today announced the closing of the sale of its global biologics manufacturing business to subsidiaries of Ferring Holding SA for $80 million.

Savient will receive the $80 million in three installments: $55 million at closing, $15 million at the first anniversary of closing and $10 million at the second anniversary of closing. Savient received its first payment of $55 million today. Savient estimates the net proceeds from this transaction over the next two years to be approximately $70 million after transaction-related expenses, taxes and the extinguishment of bank debt.

"The closing of this transaction is a significant accomplishment for Savient that allows us to concentrate on the development of our pipeline and focus on building our presence in rheumatology. We continue to execute our strategy to evolve into a world-class specialty pharmaceutical company," said Christopher Clement, Savient`s President and Chief Executive Officer. "Just one year after announcing our new strategic plan, Puricase is poised to enter Phase III clinical trials, Rosemont shows continued solid growth, and we have eliminated all of our debt and improved our balance sheet. We will continue to execute our strategy of focusing on addressing the unmet medical needs of patients, and continue to position Savient to play a significant role within the rheumatology community."

In connection with the closing, Savient`s co-promotion agreement with Ferring for Euflexxa(TM) (1% Sodium Hyaluronate), which was previously referred to as Nuflexxa, became effective on July 15, 2005. Euflexxa is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. Savient will receive 50% of the global revenues of Euflexxa above agreed upon revenue thresholds. Savient will invest up to $20 million in its sales force and other marketing contributions over the first two calendar years of the agreement.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc., an emerging specialty pharmaceuticals company, is engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs in both niche and broader markets. Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company`s subsidiary, Rosemont Pharmaceuticals Limited, develops, manufactures, and markets through its own sales force oral liquid formulations of prescription products for the UK pharmaceutical market. Savient`s product Mircette(R), an oral contraceptive, is marketed by its licensee, Organon, Inc. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Savient`s news releases and other information are available on the Company`s website at www.savientpharma.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding the Company`s strategy, expected future financial position, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, the statements regarding the estimated net proceeds from the sale of the global biologics manufacturing business, the continued implementation of the Company`s strategic plan, the development of the Company`s pipeline, the commencement of Phase III clinical trials for Puricase and growth at Rosemont are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company`s business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, delay or failure in developing Prosaptide, Puricase and other product candidates; difficulties of expanding the Company`s product portfolio through in-licensing; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company`s products; economic, political and other risks associated with foreign operations; risks of maintaining protection for the Company`s intellectual property; risks of an adverse determination in on-going or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company`s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company`s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not assume any obligation to update any forward-looking statements.

SOURCE: Savient Pharmaceuticals, Inc.

The Ruth Group
(Investors)
Francesca DeMartino, 646-536-7024
[e-mail]
or
(Media)
Janine McCargo, 646-536-7033
[e-mail]
or
Savient Pharmaceuticals, Inc.
Jenene Thomas, 732-565-4716
[e-mail]


Copyright Business Wire 2005

[blb]

Savient Pharmaceuticals Meets with FDA for End-of-Phase 2 Review of Puricase(R); Phase 3 Trial Expected to Commence in First Quarter of 2006
THURSDAY, JULY 28, 2005 6:30 AM
- BusinessWire

EAST BRUNSWICK, N.J., Jul 28, 2005 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (SVNT) , an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that it completed its previously scheduled end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for Puricase(R), Savient`s drug candidate for the treatment of refractory gout. The Company will continue to work with the FDA to finalize the details of the Phase 3 clinical program designed to evaluate the drug`s effectiveness in the control of uric acid and multiple clinical outcomes. Additionally, the Company has elected to submit a Special Protocol Assessment (SPA) to the FDA for the Phase 3 program.

The SPA is a formal process that establishes a binding, written agreement between the FDA and the sponsoring company regarding clinical trial design, endpoints, study conduct, data analysis, and other fundamentals of the study protocol.

"We are pleased with the results of this meeting and look forward to working diligently with the FDA to complete the SPA process and initiate our Phase 3 clinical program for Puricase. Our decision to submit an SPA will reduce the regulatory risk for Puricase and provide a clear path to marketing approval," commented Christopher Clement, President and Chief Executive Officer of Savient. "Thus far, Puricase has demonstrated encouraging results and we remain confident in its novel therapeutic potential to treat severe refractory gout."

The Company expects to initiate the Phase 3 program for Puricase during the first quarter of 2006. In May of 2005, Savient reported positive top-line Phase 2 clinical trial results for Puricase. Results demonstrated efficacy in reducing uric acid levels and indicated appropriate dosing for Phase 3. Additionally, during the Phase 2 study there were encouraging anecdotal reports of clinical benefits appearing within the 3-month study period, such as eradication of gout tophi and improvements in joint function and the patients` sense of well being. These outcomes will be studied formally in Phase 3, which could provide, for the first time, the first basis for a disease-modifying clinical benefit in patients with severe gout.

About Puricase

Puricase is a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase) for the treatment of patients with severe gout for whom conventional therapy is contraindicated or has been ineffective. The Company estimates approximately 35,000 to 50,000 patients in the United States. In February 2001, Savient received FDA Orphan Drug designation for Puricase.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc., an emerging specialty pharmaceuticals company, is engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs in both niche and broader markets. Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company`s subsidiary, Rosemont Pharmaceuticals Limited, develops, manufactures, and markets through its own sales force oral liquid formulations of prescription products for the UK pharmaceutical market. Savient`s product Mircette(R), an oral contraceptive, is marketed by its licensee, Organon, Inc. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Savient`s news releases and other information are available on the Company`s website at www.savientpharma.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding the Company`s strategy, expected future financial position, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, the statements regarding the estimated net proceeds from the sale of the global biologics manufacturing business, the continued implementation of the Company`s strategic plan, the development of the Company`s pipeline, the commencement of Phase 3 clinical trials for Puricase and growth at Rosemont are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company`s business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, delay or failure in developing Prosaptide, Puricase and other product candidates; difficulties of expanding the Company`s product portfolio through in-licensing; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company`s products; economic, political and other risks associated with foreign operations; risks of maintaining protection for the Company`s intellectual property; risks of an adverse determination in on-going or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company`s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company`s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not assume any obligation to update any forward-looking statements.

SOURCE: Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc.
Jenene Thomas, 732-565-4716
[e-mail]
or
The Ruth Group
Investors:
Francesca DeMartino, 646-536-7024
[e-mail]
or
Media:
Janine McCargo, 646-536-7033
[e-mail]


Copyright Business Wire 2005

[blb]

Savient Pharmaceuticals Reports Unaudited Results for Second Quarter 2005; Management Pleased with Progress Since a Year Ago; Corrected Customer Product Returns Data Reduces Reserve Requirements Retroactive to First Quarter 2005

TUESDAY, AUGUST 09, 2005 6:36 AM
- BusinessWire

EAST BRUNSWICK, N.J., Aug 09, 2005 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc., (SVNT) an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, announced today unaudited results for the second quarter 2005.

For the three months ended June 30, 2005, total revenues were $32.3 million, up from $17.7 million for the same period a year ago. The net loss for the second quarter was $3.4 million, or 5 cents per share, compared to a net loss of $31.9 million, or 53 cents per share, for the same period a year ago. The prior year quarter included a $16.3 million, or 27 cents per share, valuation allowance against the Company`s deferred tax assets because of uncertainty with respect to the realization of those tax benefits.

For the six months, ended June 30, 2005, total revenues were $56.8 up from $51.1 million for the same period a year ago. The net loss for the six-month period was $5.8 million, or 9 cents per share, compared to a net loss of $30.7 million, or 51 cents per share, for the same period a year ago, including the aforementioned $16.3 million, or 27 cents per share, valuation allowance.

Christopher Clement, President and Chief Executive Officer of Savient, said, "In the first quarter of this year, we saw an increase in customer product return notifications for Oxandrin. Based upon those notifications, which usually precede the actual return of product by several weeks, we were required to increase our overall reserve for such returns by $1.5 million in the first quarter of this year. Later in the second quarter, the actual goods returned by the customer were a small fraction of the units originally reported. As a result, we will be restating the first quarter 2005 results. The financial statements previously filed on Form 10-Q for the three months ended March 31, 2005 should no longer be relied upon. Our reported results for the first quarter, when amended with the SEC, will improve from a previously reported loss of 6 cents per share to a loss of 4 cents per share. Reported revenues for the first quarter 2005 will also increase from $23.0 million to $24.5 million."

Clement continued, "Just over a year ago, we announced a strategy to reposition Savient as a world-class specialty pharmaceutical company. Today, our business is focused on the development and expansion of our clinical pipeline and extending the geographic reach of Rosemont, our oral liquids business. Moreover, the completion of the sale of the global biologics manufacturing business early in the third quarter has provided Savient with significant funding to advance each of these efforts.

"Our positive end-of-Phase 2 meeting with the FDA for Puricase(R) has given us a lot to look forward to in the coming months. We will enter the Phase 3 development program with clearly defined, FDA-reviewed endpoints and methodologies for the evaluation of Puricase`s efficacy. Those endpoints will include not only the measurement of uric acid levels but also important clinical outcomes such as the frequency of gout flares, reduction in burden of tophi, joint counts and an overall improvement in patient-reported outcomes.

"Our results this quarter are encouraging and a reflection of our increasingly focused efforts. We continue to see growth at Rosemont, albeit slower than our historical rate due to temporary disruptions caused by the FDA`s inspection of our U.K.-based manufacturing facility. Nevertheless, Rosemont`s EBITDA, or operating income margin before corporate and non-cash charges, continued to be in excess of 40% for the quarter. The geographic expansion of this business, particularly in the U.S., will remain a key focus moving forward."

Clement highlighted several recent developments:

-- Closed the sale of the global biologics manufacturing business to Ferring on July 18, 2005 and received the initial $55 million in cash;

-- FDA completed their site inspection of the Rosemont oral liquids manufacturing facility in conjunction with their review of the Soltamox NDA, submitted in December of last year;

-- Completed positive end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for Puricase;

-- Notified of acceptance of two Puricase abstracts for presentation at the November 2005 Annual Meeting of the American College of Rheumatology; and

-- Notified of the Company`s addition to the Russell 3000(R) and New Russell Microcap(TM) Indexes.

Quarter Ended June 30, 2005

Revenues

-- Total revenues for the three months ended June 30, 2005, nearly doubled to $32.3 million compared to $17.7 million during the same period a year ago.

-- Net product sales doubled to $28.8 million compared to $14.3 million during the same period a year ago.

-- Net sales of Oxandrin in the second quarter were $12.5 million compared to less than $100,000 during the same period a year ago; the increase was attributable to the discontinuation of wholesaler purchase incentives in the second quarter of last year which negatively impacted sales for that period.

-- Net sales of Rosemont`s oral liquid pharmaceuticals increased 8% to $9.3 million compared to $8.6 million during the same period a year ago; measured in pounds sterling, sales increased only 5% reflecting a significant increase in backorders as a result of the temporary disruptions caused by the U.S. FDA inspection.

-- Total revenues for the global biologics manufacturing business increased 18% to $8.4 million compared to $7.1 million during the same period a year ago driven primarily by higher sales of human growth hormone.

Expenses

-- Total expenses for the second quarter were $34.2 million increasing 6% from $32.4 million during the same period a year ago. The increase reflects the higher sales volumes and related cost of sales, higher product development costs and pre-marketing expenses incurred for Euflexxa in the U.S. offset, in part, by lower litigation settlement costs and the absence of last year`s one-time retirement expense.

Other Net Expenses

-- Other net expenses of $0.4 million compared favorably to $0.8 million during the same period a year ago primarily as a result of lower interest expense resulting from the repayment of debt as of April 30, 2005.

Income Taxes

-- Provision for income taxes of $1.1 million compared to $16.5 million a year ago which reflected primarily a $16.3 million valuation allowance against the Company`s deferred tax assets in June 2004 because of uncertainty with respect to the realization of those deferred tax benefits.

Balance Sheet

-- Savient had cash, cash equivalents and short-term investments of $16.1 million at June 30, 2005, down from $25.3 million at year end, reflecting primarily the repayment of $5.7 million in debt and other costs and payments attributable to the divestiture of the global biologics manufacturing business which closed on July 18, 2005.

Six Months ended June 30, 2005

Revenues

-- Total revenues for the six months ended June 30, 2005 were $56.8 million compared to $51.1 million during the same period a year ago.

-- Net product sales were $53.0 million compared to $46.5 million a year ago.

-- Net product sales of Rosemont`s oral liquid pharmaceuticals increased 16% to $18.4 million compared to $15.9 million during the same period a year ago; measured in pounds sterling, sales increased 13% versus a year ago.

-- Net sales of Oxandrin were $22.3 million compared to $18.5 million a year ago; the increase was primarily attributable to the discontinuation of wholesaler purchase incentives in the second quarter of last year which negatively impacted sales for that period.

-- Total revenues for the global biologics manufacturing business increased to $12.7 million compared to $11.4 million a year ago, driven largely by higher sales of human growth hormone.

Expenses

-- Total expenses for the first six months of 2005 were $62.7 million down 2% from $64.1 million during the same period a year ago; the decrease reflects higher sales volumes and cost of products sales more than offset by lower development costs for Puricase and Prosaptide, lower sales and marketing expense for Oxandrin and the absence of last year`s one-time retirement expense.

Other Net Income

-- Other net income of $1.7 million compared to other net losses of $0.7 million during the same period a year ago, primarily attributable to the receipt of settlement proceeds from intellectual property litigation in 2005.

Income Taxes

-- Provision for income taxes of $1.4 million compared to $17.0 million a year ago which reflected primarily a $16.3 million valuation allowance against the Company`s deferred tax assets in June 2004 because of uncertainty with respect to the realization of those deferred tax benefits.

Clement concluded, "Over the past year, we have made significant progress and can now look ahead with a definitive plan for the full development of our clinical pipeline with the funding necessary to achieve it."

The Company is making every effort to file by today`s deadline its Form 10-Q for the quarter and six-months ended June 30, 2005 and its restated Form 10-Q/A giving effect to the aforementioned correction in returned goods reserves for the quarter-ended March 31, 2005. However, in the event that it is unable to do so, the Company will file for an extension on Form 12b-25.

Savient will host a conference call/live webcast today to review second quarter 2005 results today, August 9, 2005, at 11:00 a.m. EDT.

The live webcast can be accessed under the Webcast page under the News section of Savient`s website at www.savientpharma.com and will be archived through August 23, 2005.

In addition, an audio replay will be available until August 23, 2005. The replay numbers are [phone] for domestic callers and [phone] for international callers. The replay access code is 4891523.

About Savient Pharmaceuticals, Inc.

Based in East Brunswick, New Jersey, Savient Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing, manufacturing and marketing novel therapeutic products that address unmet medical needs. The Company`s lead product development candidate, Puricase(R), for the treatment of refractory gout has reported positive Phase 1 and 2 clinical data. Savient`s experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late stage compounds and exploring co-promotion and co-development opportunities that fit the Company`s expertise in specialty pharmaceuticals and initial focus in rheumatology. The Company`s operations also include a wholly-owned U.K. subsidiary, Rosemont Pharmaceuticals Ltd., which develops, manufactures and markets liquid formulations of prescription pharmaceutical products. Rosemont`s product portfolio includes over 90 liquid formulations primarily targeting the geriatric population. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on the Company can be accessed by visiting www.savientpharma.com (http://www.savientpharma.com/).

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding the Company`s strategy, expected future financial position, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, the statements regarding the estimated net proceeds from the sale of the global biologics manufacturing business, the continued implementation of the Company`s strategic plan, the development of the Company`s pipeline, the commencement of Phase 3 clinical trials for Puricase and growth at Rosemont are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company`s business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, delay or failure in developing Prosaptide, Puricase and other product candidates; difficulties of expanding the Company`s product portfolio through in-licensing; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company`s products; economic, political and other risks associated with foreign operations; risks of maintaining protection for the Company`s intellectual property; risks of an adverse determination in on-going or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company`s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company`s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not assume any obligation to update any forward-looking statements.

SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands except per share data)

Six Months Ended June 30,
2005 2004
-------------- --------------
Revenues:
Product sales, net 52,971 46,543
Royalties and other revenues 3,809 4,548
-------------- --------------
Total revenues 56,780 51,091
-------------- --------------

Expenses:
Cost of sales 19,500 16,227
Research and development 14,522 15,546
Marketing and sales 11,689 12,534
General and administrative 12,592 12,767
Retirement - 2,110
Commissions and royalties 2,445 2,910
Amortization of intangibles
associated with acquisitions 2,025 2,025
-------------- --------------
Total expenses 62,773 64,119
-------------- --------------

Operating (loss) income (5,993) (13,028)
Other income (expense) - net 1,652 (696)
-------------- --------------
(Loss) income before income taxes (4,341) (13,724)
Income tax expense 1,416 16,986
-------------- --------------
Net (Loss) Income (5,757) (30,710)
============== ==============

(Loss) earnings per common share:
Basic:
Net (loss) income (0.09) (0.51)
============== ==============
Diluted:
Net (loss) income (0.09) (0.51)
============== ==============

Weighted average number of common
and common equivalent shares:
Basic 60,635 59,849
============== ==============
Diluted 60,635 59,849
============== ==============



SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands except per share data)

Three Months Ended June 30,
2005 2004
-------------- --------------
Revenues:
Product sales, net 28,849 14,342
Royalties and other revenues 3,443 3,346
-------------- --------------
Total revenues 32,292 17,688
-------------- --------------

Expenses:
Cost of sales 10,779 7,576
Research and development 8,240 6,882
Marketing and sales 6,535 5,868
General and administrative 6,415 7,395
Retirement - 2,110
Commissions and royalties 1,221 1,507
Amortization of intangibles
associated with acquisitions 1,012 1,012
-------------- --------------
Total expenses 34,202 32,350
-------------- --------------

Operating (loss) income (1,910) (14,662)
Other income (expense) - net (405) (769)
-------------- --------------
(Loss) income before income taxes (2,315) (15,431)
Income tax expense 1,084 16,457
-------------- --------------
Net (Loss) Income (3,399) (31,888)
============== ==============

(Loss) earnings per common share:
Basic:
Net (loss) income (0.05) (0.53)
============== ==============
Diluted:
Net (loss) income (0.05) (0.53)
============== ==============

Weighted average number of common
and common equivalent shares:
Basic 60,722 59,962
============== ==============
Diluted 60,722 59,962
============== ==============



SAVIENT PHARMACEUTICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)


June 30, 2005 December 31,
(unaudited) 2004
-------------- --------------
Assets:
Cash, cash equivalents and short-term
investments 16,138 25,282
Accounts receivable, net 13,935 15,537
Inventories, net 8,627 15,317
Other current assets 5,290 3,444
Assets available for sale 74,150 79,268
-------------- --------------
Total current assets 118,140 138,848

Property and equipment, net 6,669 6,985
Intangible assets, net 69,663 71,688
Goodwill 40,121 40,121
Other long term-assets 1,365 2,946
-------------- --------------
Total assets 235,958 260,588
============== ==============

Liabilities and stockholders` equity:
Current portion of long-term debt 161 5,903
Liabilities available for sale 11,255 12,742
Other current liabilities 38,295 49,598
Long-term debt 0 0
Other long-term liabilities and
deferred items 37,134 37,677
Stockholders` equity 149,113 154,668
-------------- --------------
Total liabilities and stockholders`
equity 235,958 260,588
============== ==============


Note: Certain reclassifications were made to the December 31, 2004
balances to be consistent with the presentation shown as of June 30,
2005.


SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES
RESTATEMENT OF CONSOLIDATED STATEMENT OF OPERATIONS
(unaudited)
(in thousands, except per share data)

Three Months Ended March 31, 2005
---------------------------------
As previously
reported As restated

Product sales, net $ 22,615 $ 24,122
Total revenues 22,981 24,488
Operating income (loss) (5,590) (4,083)
Income (loss) before income taxes (3,533) (2,026)
Net Income (loss) $ (3,865) $ (2,358)
Earnings (loss) per common share:
Basic $ (0.06) $ (0.04)
Diluted $ (0.06) $ (0.04)



SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES
RESTATEMENT OF CONSOLIDATED BALANCE SHEET
(unaudited)
(in thousands, except per share data)

Three Months Ended March 31, 2005
---------------------------------
As previously
reported As restated

Accounts receivable, net $ 2,692 $ 1,185
Total current assets 120,338 118,831
Total assets $ 239,350 $ 237,843

Accumulated deficit (69,561) (71,068)
Total stockholders` equity 152,390 150,883
Total liabilities and stockholders`
equity $ 239,350 $ 237,843


SOURCE: Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc.
Jenene Thomas, 732-565-4716
[e-mail]
or
Investors/Media:
The Ruth Group
Francesca DeMartino/Janine McCargo
646-536-7024/7033
[e-mail]
[e-mail]


Copyright Business Wire 2005

[parakeet_luck]

Savient Receives Nasdaq Delisting Notice Related to Late Form 10-Q
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, announced that it has received a Nasdaq staff determination letter stating that the Company is not in compliance with Nasdaq Marketplace Rule 4310(c)(14) because the Company has not timely filed its Quarterly Report on Form 10-Q for the period ended June 30, 2005, and that the Company`s common stock is, therefore, subject to delisting from The Nasdaq Stock Market. As a result, an "E" will be added to the trading symbol for the Company`s common stock, which will begin trading under the symbol "SVNTE" effective at the opening of business on August 19, 2005.

The Company intends to request a hearing before a Nasdaq Listing Qualifications Panel to review the staff determination and to request that the Company`s listing be continued while the Company completes the work necessary to comply with the listing requirement. The Company expects that its common stock will remain listed on The Nasdaq Stock Market pending the outcome of the Nasdaq Listing Qualifications Panel`s decision. However, the Company cannot provide any assurance that the Nasdaq Listing Qualifications Panel will grant its request for continued listing on The Nasdaq Stock Market.

As previously announced, in connection with the Company`s announcement of its financial results for the quarter ended June 30, 2005, the Company determined that it had made an error in recording its reserve for returns in the first quarter of 2005. The Company determines its reserves for sales returns based, in part, on notifications received from customers advising the Company through its third-party fulfillment center of their intent to return product. The Company subsequently determined that certain of those reported returns were in error in that actual units of product returned were significantly less than the amounts originally expected to be returned. This occurred in part because the customer`s request was not fully understood by the returned goods coordinator at the third-party fulfillment center.

The Company is continuing to evaluate the nature and extent of the errors described above. As promptly as practicable following the completion of this evaluation, the Company intends to file its Quarterly Report on Form 10-Q for the period ended June 30, 2005 and such amendments to any prior filing that the Company determines are necessary and to fully comply with all other requirements for continued listing on The Nasdaq Stock Market.

About Savient Pharmaceuticals (Nachrichten), Inc.

Based in East Brunswick, New Jersey, Savient Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing, manufacturing and marketing novel therapeutic products that address unmet medical needs. The Company`s lead product development candidate, Puricase(R), for the treatment of refractory gout has reported positive Phase 1 and 2 clinical data. Savient`s experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late stage compounds and exploring co-promotion and co-development opportunities that fit the Company`s expertise in specialty pharmaceuticals and initial focus in rheumatology. The Company`s operations also include a wholly-owned U.K. subsidiary, Rosemont Pharmaceuticals Ltd., which develops, manufactures and markets liquid formulations of prescription pharmaceutical products. Rosemont`s product portfolio includes over 90 liquid formulations primarily targeting the geriatric population. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on the Company can be accessed by visiting www.savientpharma.com (http://www.savientpharma.com/).

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding the Company`s strategy, expected future financial position, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, the statements as to the possible outcome of the Company`s request for continued listing on The Nasdaq Stock Market, the timing of the filing of the Company`s June 30, 2005 Form 10-Q, whether any amendments to any prior filing are necessary, and the timing of the filing of any such amendments are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company`s business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, delisting of the Company`s common stock from The Nasdaq Stock Market, delay or failure in developing Prosaptide, Puricase and other product candidates; difficulties of expanding the Company`s product portfolio through in-licensing; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company`s products; economic, political and other risks associated with foreign operations; risks of maintaining protection for the Company`s intellectual property; risks of an adverse determination in on-going or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company`s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company`s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not assume any obligation to update any forward-looking statements.

[bioperformer]

vorbörslich schon mal 43% im Minus.

liegt wohl am delisting??

[blb]

Woher hast du bitte diese Falschinfo??

[bioperformer]

der Kurs war vorbörslich von INET, das mit dem Delisting hier im Anschluß.


Savient Receives Delisting Letter
Friday August 19, 11:06 am ET
Savient Pharmaceuticals Receives Nasdaq Delisting Notice After Failing to File 10-Q on Time


EAST BRUNSWICK, N.J. (AP) -- Savient Pharmaceuticals Inc. on Friday said its stock is subject to delisting from the Nasdaq, after the drug development company failed to file its latest quarterly report on time.
ADVERTISEMENT



Savient said the Nasdaq has informed the company that it is not in compliance with market rules for failing to file its Form 10-Q for the period ended June 30.

The warning comes after Savient said Monday it would not meet an extended deadline for filing the quarterly report with securities regulators, citing a probe of possible accounting errors related to reserves for customer returns.

Savient said it would request a hearing with the Nasdaq and ask for its stock to remain listed as it completes the quarterly report. The company said it plans to file the report and any necessary changes to previous results "as promptly as practicable."

As a result of Savient`s noncompliance with Nasdaq listing rules, an "E" will be added to its ticker symbol, which will begin trading under SVNTE starting immediately. Shares of Savient added 7 cents to $4.16 on the Nasdaq.

[blb]

Soweit ich das verstehe wird alles daran gesetzt, dass man wieder das Listing zurückbekommt. Kürzel nun SVNTE. Kurs stabil...

[blb]

Schon etwas älter...

Barr, Organon and Savient Announce Letter of Intent Regarding Mircette(R)
THURSDAY, SEPTEMBER 08, 2005 7:30 AM
- PR Newswire

WOODCLIFF LAKE and EAST BRUNSWICK, N.J., Sept 08, 2005 /PRNewswire-FirstCall via COMTEX/ -- Barr Pharmaceuticals, Inc. ("Barr") (BRL) , Organon USA Inc. and Organon (Ireland) Ltd. ("Organon"), business units of Akzo Nobel NV (AKZOY) , and Savient Pharmaceuticals, Inc. ("Savient") (SVNTE) today confirmed that Barr Pharmaceuticals, Inc. and its subsidiaries have entered into a non- binding Letter of Intent to acquire the exclusive rights to Organon`s Mircette(R) (Desogestrel/Ethinyl Estradiol) oral contraceptive product and to settle the pending patent litigation with Organon and Savient concerning Barr Laboratories, Inc.`s generic version of Mircette(R), which the Company markets under the trade name Kariva(R). The parties also confirmed that they have requested, and the District Court has agreed, to stay any further proceedings to allow the parties to negotiate definitive settlement agreements. The agreements are subject to several conditions, including negotiation of definitive agreements.

Under the proposed transaction, which is subject to antitrust approval, Barr would pay Organon $142 million to purchase the New Drug Application ("NDA") for Mircette(R) and in settlement of the patent litigation and would pay Savient $13.75 million (which would yield Savient $10.75 million, net of pass-through royalties to Savient`s licensor) in settlement of the patent litigation and as prepaid future royalties on sales of Mircette(R) and Kariva(R). Barr anticipates taking a charge of $62.3 million, or approximately $0.37 earnings per diluted share, in its financial statement for the quarter and year ended June 30, 2005, related to the transaction. Upon completion of the transaction, Barr`s Duramed Pharmaceuticals subsidiary intends to promote Mircette(R) to female healthcare practitioners.

"This acquisition ensures that there will continue to be both a brand and generic version of Mircette(R) in the marketplace, and removes the risk of a possible injunction against the continued sale of Kariva(R)" said Bruce L. Downey, Barr`s Chairman and CEO.

The patent litigation is currently before the U.S. District Court for the District of New Jersey. In April 2002, following a summary judgment ruling by the Court that Barr`s Kariva(R) product did not infringe the patent at issue, Barr launched Kariva(R), a generic equivalent to Organon`s Mircette(R) oral contraceptive. In April 2003, the U.S. Court of Appeals for the Federal Circuit reversed and remanded the case back to the U.S. District Court for the District of New Jersey for additional fact finding. Following the acquisition of Duramed in October 2001, Barr commenced manufacturing and marketing the Kariva(R) product, and was named as an additional defendant in the suit.

On June 30, 2005, Barr and Organon filed the Letter of Intent with the Federal Trade Commission ("FTC") pursuant to the Hart Scott Rodino Antitrust Improvements Act. On August 1, 2005, the FTC issued a second request for information regarding the proposed transaction.

Mircette(R) is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Mircette(R) is available in a 28-tablet regimen that represents a combination of desogestrel/ethinyl estradiol and ethinyl estradiol.

About Barr

Barr Pharmaceuticals, Inc. is a holding company, whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceuticals. A research-intensive pharmaceutical company, Barr currently manufactures and markets more than 100 different dosage forms and strengths of over 70 different generic pharmaceutical products, including 22 oral contraceptive products, representing the largest category of the Company`s generic portfolio, and 13 proprietary pharmaceutical products, largely concentrated in the female healthcare arena.

About Savient

Based in East Brunswick, New Jersey, Savient Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing, manufacturing and marketing novel therapeutic products that address unmet medical needs. The Company`s lead product development candidate, Puricase(R), for the treatment of refractory gout has reported positive Phase 1 and 2 clinical data. Savient`s experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late stage compounds and exploring co-promotion and co-development opportunities that fit the Company`s expertise in specialty pharmaceuticals and initial focus in rheumatology. The Company`s operations also include a wholly-owned U.K. subsidiary, Rosemont Pharmaceuticals Ltd., which develops, manufactures and markets liquid formulations of prescription pharmaceutical products. Rosemont`s product portfolio includes over 90 liquid formulations primarily targeting the geriatric population. Further information on the Company can be accessed by visiting http://www.savientpharma.com.

Barr`s Forward-Looking Statements

Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company`s business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies and products we acquire and implementing our new enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; changes in generally accepted accounting principles; and other risks detailed from time-to-time in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the fiscal year ended June 30, 2004.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.

Savient`s Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding Savient`s strategy, expected future financial position, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, the statements as to the possible outcome of Savient`s request for continued listing on The Nasdaq Stock Market are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about Savient`s business and the biopharmaceutical and specialty pharmaceutical industries in which Savient operates. Such risks and uncertainties include, but are not limited to, delisting of Savient`s common stock from The Nasdaq Stock Market, delay or failure in developing Prosaptide, Puricase and other product candidates; difficulties of expanding Savient`s product portfolio through in-licensing; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of Savient`s products; economic, political and other risks associated with foreign operations; risks of maintaining protection for Savient`s intellectual property; risks of an adverse determination in on-going or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries. Savient may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on Savient`s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Savient makes. Savient`s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that Savient may make. Savient does not assume any obligation to update any forward-looking statements.

SOURCE Barr Pharmaceuticals, Inc.

Carol A. Cox of Barr Pharmaceuticals, Inc., [phone], [e-mail];
Jenene D. Thomas of Savient Pharmaceuticals, Inc., [phone],
[e-mail]


http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved. ********************************************************************** As of Sunday, 09-04-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 08-16-2005 for AKZOY @ $41.43. As of Sunday, 09-04-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 07-21-2005 for BRL @ $46.91. (C) 2005 Comtex News Network, Inc. All rights reserved.

[blb]

Savient Pharmaceuticals Finalizes Agreement for the Settlement of Mircette(R) Litigation; Transaction Terminates Patent Litigation and Results in $13.75 Million Payment To Savient
FRIDAY, DECEMBER 02, 2005 2:30 AM
- BusinessWire

EAST BRUNSWICK, N.J., Dec 02, 2005 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. ("Savient") (SVNTE) , an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, announced today that it has concluded with Barr Pharmaceuticals, Inc. ("Barr") (BRL) , Organon USA Inc. and Organon (Ireland) Ltd. ("Organon"), business units of Akzo Nobel NV (AKZOY) , an agreement for the settlement of the ongoing patent litigation regarding Barr`s generic version of Mircette(R), which Barr markets under the trade name Kariva(R). Under the terms of the transaction Barr will acquire the exclusive rights to Organon`s Mircette (Desogestrel/Ethinyl Estradiol) oral contraceptive product.

Under the terms of the transaction, in settlement of the patent litigation and as prepaid future royalties on sales in the United States of Mircette and Kariva, Barr paid Savient $13.75 million, which yields Savient approximately $10.9 million, net of pass-through revenue sharing to the inventor from whom Savient acquired the patents covering Mircette.

Mircette is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Mircette is available in a 28-tablet regimen that represents a combination of desogestrel/ethinyl estradiol and ethinyl estradiol.

About Savient Pharmaceuticals, Inc.

Based in East Brunswick, New Jersey, Savient Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing, manufacturing and marketing novel therapeutic products that address unmet medical needs. The Company`s lead product development candidate, Puricase(R), for the treatment of refractory gout has reported positive Phase 1 and 2 clinical data. Savient`s experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late stage compounds and exploring co-promotion and co-development opportunities that fit the Company`s expertise in specialty pharmaceuticals and initial focus in rheumatology. The Company`s operations also include a wholly-owned U.K. subsidiary, Rosemont Pharmaceuticals Ltd., which develops, manufactures and markets liquid formulations of prescription pharmaceutical products. Rosemont`s product portfolio includes over 90 liquid formulations primarily targeting the geriatric population. Further information on the Company can be accessed by visiting www.savientpharma.com.

SOURCE: Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc.
Jack Domeischel, 732-565-4716
[e-mail]
OR
Investors/Media:
The Ruth Group
Francesca DeMartino, 646-536-7024
[e-mail]
OR
Janine McCargo, 646-536-7033
[e-mail]


Copyright Business Wire 2005 ********************************************************************** As of Monday, 11-28-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 11-17-2005 for AKZOY @ $44.82. As of Monday, 11-28-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 09-06-2005 for BRL @ $49.20. (C) 2005 Comtex News Network, Inc. All rights reserved.

[blb]

So, jetzt ist alles wieder im Lot, Savient wird wieder unter dem Kürzel SVNT gehandelt!

Savient Regains NASDAQ Listing Requirement Compliance; Trading Symbol to be Restored to ``SVNT``
TUESDAY, JANUARY 31, 2006 2:08 PM
- BusinessWire

EAST BRUNSWICK, N.J., Jan 31, 2006 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (SVNTE) , an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that it has received written notification from the Nasdaq Listing Qualifications Panel of its determination of the Company`s compliance with the requirements for continued listing on The Nasdaq National Market. As a result of Savient`s compliance, the Company expects that its trading symbol will be restored to "SVNT" effective upon the open of the market on February 2, 2006.

About Savient

Based in East Brunswick, New Jersey, Savient Pharmaceuticals, Inc., is an emerging specialty pharmaceuticals company, is engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs in both niche and broader markets. The Company`s lead product development candidate, Puricase(R), for the treatment of refractory gout has reported positive Phase 1 and 2 clinical data. Savient`s experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late stage compounds and exploring co-promotion and co-development opportunities that fit the Company`s expertise in specialty pharmaceuticals and initial focus in rheumatology. Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company`s subsidiary, Rosemont Pharmaceuticals Limited, develops, manufactures, and markets through its own sales force oral liquid formulations of prescription products for the UK pharmaceutical market. Rosemont`s product portfolio includes over 90 liquid formulations primarily targeting the geriatric population. Savient`s product Mircette(R), an oral contraceptive, is marketed by its licensee, Duramed Pharmaceuticals, Inc. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on the Company can be accessed by visiting www.savientpharma.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding the Company`s strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, the statements regarding the continued listing of the Company`s common stock on The Nasdaq Stock Market are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company`s business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the Company`s ability to complete the restatement of its financial statements described above on a timely basis, delay or failure in developing Puricase and other product candidates; difficulties of expanding the Company`s product portfolio through in-licensing; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; the Company`s continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company`s products; economic, political and other risks associated with foreign operations; risks of maintaining protection for the Company`s intellectual property; risks of an adverse determination in on-going or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company`s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company`s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not assume any obligation to update any forward-looking statements.

SOURCE: Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc.
Jack Domeischel, 732-565-4716
[e-mail]
or
Investors:
The Ruth Group
Francesca DeMartino, 646-536-7024
[e-mail]


Copyright Business Wire 2006